lenalidomide has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cardis, MA; Kirkorian, AY; Sherman, MA; Srinivasalu, H | 1 |
| Li, M; Wang, Q; Wang, X; Zeng, X | 1 |
| Aikawa, NE; Bonfa, E; Heise, CO; Pasoto, SG; Romiti, R; Silva, CA; Yuki, EFN | 1 |
| Bergeret, B; Bessis, D; Dandurand, M; Dereure, O; Du-Thanh, A; Lipsker, D; Reymann, V; Terrail, N | 1 |
| Aitmehdi, R; Amoura, Z; Arnaud, L; Barbaud, A; Chasset, F; Cohen-Aubart, F; Costedoat-Chalumeau, N; de Risi-Pugliese, T; Fain, O; Francès, C; Haroche, J; Hie, M; Le Guern, V; Mathian, A; Mékinian, A; Monfort, JB; Pha, M; Senet, P | 1 |
| Nutan, F; Ortega-Loayza, AG | 1 |
| Dalm, VA; van Hagen, PM | 1 |
| Alaibac, M; Lo Nigro, A; Peserico, A; Russo, I; Stan, R; Zattra, E | 1 |
| Krathen, M; Okawa, J; Okon, L; Propert, K; Rose, M; Rosenbach, M; Werth, V | 1 |
| Davis, MD; Kindle, SA; Pittelkow, MR; Sciallis, GF; Wetter, DA | 1 |
| Chasset, F; Cordel, N; Fennira, F; Francès, C; Petit, A; Soubrier, M | 1 |
| Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY | 1 |
| Aberer, E; Bata-Csörgő, Z; Caproni, M; Dreher, A; Frances, C; Gläser, R; Klötgen, HW; Kuhn, A; Landmann, A; Marinovic, B; Nyberg, F; Olteanu, R; Ranki, A; Szepietowski, JC; Volc-Platzer, B | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
| Braunstein, I; Goodman, NG; Kovarik, CL; Krathen, M; Luning Prak, E; Okawa, J; Rosenbach, M; Shah, A; Werth, VP | 1 |
| Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M | 1 |
4 review(s) available for lenalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Retrospective Studies; Thalidomide | 2021 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Thalidomide | 2017 |
TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
Topics: Animals; Antibodies, Blocking; Clinical Trials as Topic; Drug Resistance; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Interferons; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
2 trial(s) available for lenalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Patient Safety; Prospective Studies; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Remission Induction; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Thalidomide; Treatment Outcome; Vomiting | 2012 |
10 other study(ies) available for lenalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Topics: Child; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Thalidomide | 2023 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thalidomide | 2023 |
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Treatment Outcome | 2021 |
Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Efficacy of lenalidomide in refractory lupus pernio.
Topics: Chilblains; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Thalidomide | 2013 |
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Topics: Academic Medical Centers; Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Panniculitis, Lupus Erythematosus; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Topics: Adult; Chronic Disease; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Retreatment; Thalidomide | 2016 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Prednisolone; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2017 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Dapsone; Humans; Immunosuppressive Agents; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Practice Guidelines as Topic; Retinoids; Thalidomide | 2017 |
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Topics: Adult; Female; Humans; Lenalidomide; Leukocytes; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Middle Aged; Risk Factors; Thalidomide | 2012 |